Use of second-generation antihistamines in combination treatment of ENT diseases
https://doi.org/10.21518/2079-701X-2015-15-62-65
Abstract
Currently, allergic diseases are very widespread, and their incidence is increasing at an alarming pace worldwide. [1] According to different authors, from 20 to 50% of the population in European countries suffer from allergic diseases. Large-scale epidemiological studies demonstrated that 20% of the population at least once in their lives had acute urticaria. [2, 3
About the Authors
A. I. Kryukov
Research and Clinical Otorhinolaryngology Institute named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
N. L. Kunelskaya
Research and Clinical Otorhinolaryngology Institute named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
G.Y. T Tsarapkin
Research and Clinical Otorhinolaryngology Institute named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
G. N. Izotova
Research and Clinical Otorhinolaryngology Institute named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
S. G. Arzamazov
Research and Clinical Otorhinolaryngology Institute named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
A. S. Tovmasyan
Research and Clinical Otorhinolaryngology Institute named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
References
1. Аллергические заболевания и окружающая среда. Под ред. О.К. Нетребенко и В.А. Ревякиной. М., 2007.
2. Йегер Л. Клиническая иммунология и аллергология. М.: Медицина, 1990. Т. 1. С. 155-156.
3. Фридлянд Д.Г., Гущин И.С., Порошина Ю.А. Сравнительное изучение антигистаминной и антиаллергической активности некоторых противогистаминных препаратов. Тер. архив, 2002. 3: 67-72.
4. Лопатин А.С. Ринит: руководство для врачей. М.: Литтерра, 2010. С. 215.
5. Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. М.: Медицина, 2000. 422 с.
6. Петровская Т.Ю., Лопатин А.С., Федотенко Е.С., Сергеева Т.А. Сравнительный анализ эффективности современных Н1-блокаторов у больных интермиттирующим (сезонным) аллергическим ринитом. Российская ринология, 2009. 1: 19-23.
7. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт, 1998.
8. Инструкция по медицинскому применению препарата Дезлоратадин (Эриус®).
9. Wachs M., Proud D., Lichtenstein L.M. et al. Observations on the pathogenesis of nasal priming. J. Allergy Clin. Immunol., 1989. 84: 492-501.
10. Simons FE. H1-receptor antagonists. Comparative tolerability and safety. Drug Saf., 1994. 10 (5): 350-380.
11. Zareba W. et al. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol., 1997. 80 (9): 1168-1173.
12. Passalacqua G et al. Sedation from H1 antagonists: evaluation methods and experimental results. Allergol Immunopathol (Madr),1993. 21 (2): 79-83.
13. Simons FE, Simons KJ. Clinical pharmacology of H1-antihistamines. Clin Allergy Immunol, 2002. 17: 141-178.
14. Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analisis of randomized, doubl-blind, controlled trials. Allergy, 2007. 62 40: 359-366.
15. Tatar A, Parlak SN, Yayla M, Ugan RA, Polat E, Halici Z. Effects of allergic rhinitis and desloratadine on the submandibular gland in a rat allergy model. Int Forum Allergy Rhinol., 2015. 22.
16. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing? J. Investig Allergol Clin Immunol., 2013. 23(3): 141-4.
17. Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, Dimitrov V, Church MK. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol., 2010. 125(3): 676-82.
18. Lukat K, Rivas P, Roger A, Kowalski M, Botzen U, Wessel F, Sanquer F, Agache I, Izquierdo I. A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study. J Asthma
19. Allergy, 2013. 6: 31-9.
20. Torkildsen GL, Gomes P, Welch D, Gopalan G, Srinivasan S. Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms. Clin Exp Allergy, 2009. 39(7): 1052-9.
21. Bousquet J, Bachert C, Canonica GW, Mullol J, Van Cauwenberge P, Bindslev Jensen C, Fokkens WJ, Ring J, Keith P, Lorber R, Zuberbier T; ACCEPT-1 study group. Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy, 2009. 64(10): 1516-23.
22. Aberer W. Desloratadine for the Relief of Nasal and Non-nasal Allergy Symptoms: An Observational Study. Arch Drug Inf., 2009. 2(2): 17-22.
23. Holmberg K, Tonnel AB, Dreyfus I, Olsson P, Cougnard J, Mesbah K, Devillier P. Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy, 2009. 64(11): 1663-70.
24. Bousquet J, Zuberbier T, Canonica GW, Fokkens WJ, Gopalan G, Shekar T. Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. Allergy Asthma Proc., 2013. 34(3): 274-82.
25. Augustin M, Ehrle S. Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. J Eur Acad Dermatol Venereol., 2009. 23(3): 292-9.
26. DuBuske L.M. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert Opin Pharmacother., 2005. 6 (14): 2511-2523.
27. Bousquet J et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy, 2003. 58 (8): 733-741.
Review
For citations:
Kryukov AI, Kunelskaya NL, Tsarapkin GT, Izotova GN, Arzamazov SG, Tovmasyan AS. Use of second-generation antihistamines in combination treatment of ENT diseases. Meditsinskiy sovet = Medical Council. 2015;(15):62-65. (In Russ.) https://doi.org/10.21518/2079-701X-2015-15-62-65
Views:
584
Email this article 